

Product Data Sheet

Product Name: TW9
Cat. No.: GC48408

Chemical Properties

Cas. No. 2614417-90-0

SMILES CC1=C(C)C(C(C2=CC=C(Cl)C=C2)=N[C@H]3CC(NC4=CC=C(C(NC5=C(N)C=CC=C5)=O)C=C4)=O)=C(S1)N6C3=NN=C6C


Formula C₃₂H₂₈ClN₇O₂S M.Wt 610.1

Solubility DMF: 20 mg/ml, DMSO: 10 mg/ml Storage -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the tips ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution: ship with blue ice All other available size: ship with RT, or Condition blue ice upon request.

Structure



Background

TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC₅₀s = 0.074 and 0.29 μM, respectively).¹ It is selective for BD2 over BD1 in BRD4 (IC₅₀ = 0.72 μM) and for HDAC1 over HDAC2 (IC₅₀ = 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G₁ phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

1. Zhang, X., Zegar, T., Weiser, T., et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. *Int. J. Cancer* 147(10):2847-2861 (2020)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA